Adeno-associated virus (AAV) is a promising vehicle for gene therapy, which will rely on the generation of high-titer, high-purity recombinant vectors. However, numerous purification protocols can involve challenging optimization or scalability issues, and most AAV serotypes do not bind heparin or sialic acid, used for AAV2/3 or AAV4/5 purification, requiring the development of new chromatography strategies. Immobilized metal affinity chromatography (IMAC) allows for robust protein purification via affinity tags such as the hexahistidine (His 6 ) sequence. Through the combination of a diverse AAV2 library and rational peptide insertions, we have located an optimal His 6 tag insertion site within the viral capsid. This mutant and a related AAV8 variant can be purified from clarified cell lysate in a single gravity column step at infectious particle yields exceeding 90%. Furthermore, injection of IMAC-purified vector into the brain demonstrates that it mediates high-efficiency gene delivery in vivo, equivalent to that of wild-type capsid, with minimal immune cell activation. This affinity chromatography method may offer advantages in ease of purification, final vector purity, and process scalability. Moreover, a combined rational design and high-throughput library selection approach can aid in the design of enhanced viral gene delivery vectors.
INTRODUCTION
A DENO-ASSOCIATED VIRUS (AAV) is a nonpathogenic human parvovirus that requires a helper virus to replicate (Fields et al., 2001) . The single-stranded 4.6-kb DNA genome of AAV contains two open reading frames (ORFs): rep, which encodes a set of four proteins (Rep78, Rep68, Rep52, and Rep40) essential for replication of the viral genome, and cap, which encodes the structural proteins (VP1-VP3) (Srivastava et al., 1983; Samulski et al., 1989) . VP1-VP3 self-assemble into the viral icosahedral capsid, 25 nm in diameter, into which the genome is inserted (Fields et al., 2001) . The capsid then escorts the viral genome through numerous gene delivery barriers, from the point of entry into tissue to the final viral destination in a target cell nucleus. This high delivery efficiency has been harnessed for gene delivery to and long-term gene expression in a broad array of dividing and nondividing cell types in vivo (Flotte et al., 1993; Kaplitt et al., 1994; Kaspar et al., 2003) . Natural evolution has generated Ͼ100 AAV serotypes, which exhibit a diverse array of gene delivery properties (Chiorini et al., 1999; Gao et al., 2004) . AAV2 remains the most widely used to date, because of its extensive safety record and well-characterized gene delivery properties. In addition, recombinant (r)AAV2 vectors have been explored in numerous clinical trials (Kay et al., 2000; Manno et al., 2003) . However, other serotypes have also shown substantial progress (Sarkar et al., 2006) .
One challenge with rAAV vectors involves the development of a scalable, high-throughput purification protocol that can be generally applicable to all serotypes. The original purification scheme employed a virus precipitation followed by two or three rounds of ultracentrifugation through an isopycnic cesium chloride (CsCl) gradient, which also often resulted in low recovery and limited throughput and scalability (Snyder, 1996) . Advances in AAV purification have focused on enhancing viral recovery while retaining its biological activity through chromatographic methods, such as affinity and ion exchange. In particular, affinity chromatography has successfully allowed for rapid purification of AAV2 through columns packed with either a monoclonal antibody that recognizes a conformational epitope on the viral capsid (Grimm et al., 1998) or heparin, structurally similar to the heparan sulfate proteoglycan (HSPG) primary receptor for AAV2 (Clark et al., 1999; Zolotukhin et al., 1999; Auricchio et al., 2001) . Heparin affinity resins have been used to isolate high-titer rAAV2 stocks directly from clarified cell lysate at yields ranging from 30 to 75%, with few protein contaminants. Unfortunately, most novel AAV serotypes cannot bind existing affinity resins based on heparin or sialic acid (Walters et al., 2001) , creating the need for serotype-specific resins. By comparison, ion exchange is broadly applicable for the purification of multiple AAV serotypes, but it requires reoptimization of buffer conditions for each serotype (Brument et al., 2002; Kaludov et al., 2002) . As an alternative, Bartlett and coworkers have employed an avidin affinity column platform to successfully purify multiple AAV serotypes into which a biotin acceptor peptide (BAP) was engineered, although purification required use of a density gradient separation before column application (Arnold et al., 2006) . It would be advantageous to generate a rapid, robust purification method that combines the single-step efficacy of affinity resins with the generality of ion exchange.
Genetic modification of AAV has allowed for the study and design of its gene delivery properties. For example, mutagenesis studies have elucidated amino acids critical for heparan sulfate binding (Kern et al., 2003; Opie et al., 2003) as well as other regions required for infectivity (Rabinowitz et al., 1999; Wu et al., 2000; Shi et al., 2001) . In addition, numerous efforts to alter viral tropism, along with the elucidation of the AAV2 crystal structure , have led to the identification of several regions in the AAV2 capsid amenable to peptide insertions, and an increasing number of studies have introduced peptides into other AAV serotypes (Girod et al., 1999; Grifman et al., 2001; Shi et al., 2001; Muller et al., 2003; Perabo et al., 2003) . However, some peptide insertions drastically reduce viral production titers or viral infectivity, whereas others may not be functionally displayed on the capsid surface. Also, different peptide sequences inserted into the same location in the capsid may not be functionally displayed equally, and subtle differences in the sequences of flanking amino acids can yield variants with infectivities differing by several orders of magnitude (Wu et al., 2000; Shi et al., 2001) . Transposonbased saturation mutagenesis approaches have proven useful for mapping novel insertion sites with viral genomes and proteins (Brune et al., 1999; Yu and Schaffer, 2006) . We therefore employed a dual approach in which an affinity purification tag was rationally inserted at several sites, and an insertional mutagenesis library was generated and explored for other potentially permissive sites.
Immobilized metal affinity chromatography (IMAC) has broad applicability in the area of protein purification because of low cost, high loading capacity, minimal product loss, and mild solution conditions. For example, hexahistidine (His 6 ) tags bind reversibly with micromolar affinity to nickel nitrilotriacetic acid (Ni-NTA) (Porath et al., 1975; Kapanidis et al., 2001) and have been employed to purify several viral vectors via IMAC with various degrees of success (Hu et al., 2003; Ye et al., 2004; Yu and Schaffer, 2006) . Previous insertion of a flexible linker followed by a His 6 tag at the end of the AAV2 VP3 capsid protein generated infectious AAV particles with the ability to bind Ni-NTA beads (Zhang et al., 2002) . However, important results (such as purity and yield) were not reported. In a separate study, insertion of a His 6 tag severely decreased viral production levels and abolished viral infectivity (Wu et al., 2000) .
We have successfully generated two novel His 6 -containing AAV mutants, based on AAV2 and the first reported AAV8 peptide insertion, that generate high-titer rAAV vector readily and effectively purified via single-step, gravity Ni-NTA column chromatography for application in vitro and in vivo. Furthermore, the combined rational insertion and library-based approach may allow for the identification of optimal insertion sites for specific peptides in the capsid of any AAV serotype, thereby improving the process of viral vector design and application.
MATERIALS AND METHODS

Construction of AAV plasmids
To construct pXX2Not, a 1.8-kilobase linear fragment containing a portion of the backbone sequence of pXX2 (Xiao et al., 1998) was generated by polymerase chain reaction (PCR), using the primers 5Ј-GCGAAGCTTACGCGGCCGCTTGT-TAATCAATAAACCGTTTAATTCG-3Ј and 5Ј-CGGAATG-GACGATATCCCGC-3Ј with pXX2 (Xiao et al., 1998) as template. Both this product and pXX2 were digested with HindIII and ClaI, and the products were ligated to create the rAAV packaging plasmid pXX2Not. The cap sequence from AAV8 was cloned into this vector as well. To construct each peptide mutant, spliced overlap extension PCR was used to insert the His 6 peptide epitopes into the correct location, sometimes with additional flanking sequences (primer sequences and cloning details are available on request). In addition, an AAV2 library containing a randomly inserted His 6 sequence within the cap gene was packaged (Maheshri et al., 2006) and selected as previously described (Yu and Schaffer, 2006) . Briefly, the chloramphenicol resistance (Cam R ) gene was randomly inserted into a plasmid containing the AAV2 cap gene, using a transposon kit (Finnzymes, Espoo, Finland) . The resulting plasmid library was digested to excise the cap-Cam R genes, which were subsequently cloned into pSub2 (Maheshri et al., 2006) . The pSub2 plasmid library was digested with NotI before ligation to His 6 fragments phosphorylated with T4 polynucleotide kinase. The His 6 insert was constructed with the following oligonucleotides, with the histidine codons shown in boldface: 5Ј-GGCCGGT-CACCACCACCACCACCACTC-3Ј and 5Ј-GGCCGAGTG-GTGGTGGTGGTGGTGACC-3Ј.
Cell lines and vector production
HEK293T, HeLa, CHO K1, CHO pgsA, and CHO pgsD were cultured in Iscove's modified Dulbecco's medium (IMDM; Mediatech, Herndon, VA) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and 1% penicillin and streptomycin (Invitrogen) at 37°C and 5% CO 2 . All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). AAV293 cells (Stratagene, La Jolla, CA) were cultured in Dulbecco's modified medium (DMEM) with 10% fetal bovine serum and 1% penicillin and streptomycin at 37°C and 5% CO 2 .
rAAV was produced as previously described (Kaspar et al., 2003; Maheshri et al., 2006) . Briefly, in a 15-cm plate of ϳ80% confluent AAV293 cells (Stratagene), ϳ15 g of pAAV CMV-GFP, 15 g of pHelper (Stratagene), and 15 g of one of the modified pXX2Not plasmids were transfected by the calcium phosphate method. Viral vectors were harvested as previously described (Maheshri et al., 2006) . Vector packaged in wild-type capsid was purified via an iodixanol gradient followed by heparin column chromatography (Zolotukhin et al., 1999) . DNaseresistant genomic titers were determined by quantitative PCR, and infectious titers were determined by flow cytometry as previously described (Maheshri et al., 2006) .
Ni-NTA purification of viral vectors
A mixture of 1 volume of cell lysate containing virus, 0.5 volume of binding buffer (10 mM Tris [pH 8.0], 300 mM NaCl, and 20 mM imidazole), and 500 l of 50% Ni-NTA agarose (Qiagen, Valencia, CA) was agitated gently overnight at 4°C. This mixture was then loaded onto a plastic column (Kontes, Vineland, NJ) before washing with 5 ml of wash buffer (10 mM Tris [pH 8.0], 50 mM imidazole) and eluting with 2-3 ml of elution buffer (10 mM Tris [pH 8.0], 500 mM imidazole). Finally, the eluted virus was buffer exchanged into Tris-buffered saline (TBS) and concentrated with Microcon spin columns (Millipore, Billerica, MA) according to the manufacturer's instructions.
Equivalent amounts of each column sample from a largescale purification scheme were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were detected with a silver stain kit (Bio-Rad, Hercules, CA). The DMEM and viral cell lysate samples analyzed on the same gel were diluted 1:10 to prevent oversaturation of the silver stain signal.
For Western blot analysis, equivalent amounts of green fluorescent protein (GFP) vector packaged with wild-type AAV2 and His 6 capsids were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose blot. The blot was blocked in Tris-buffered saline with 3% bovine serum albumin and incubated with penta-His antibody (Qiagen) according to the manufacturer's instructions. The blots were then developed by enhanced chemiluminescence (ECL) detection assay (GE Healthcare Life Sciences, Piscataway, NJ).
In vitro characterization of viral vectors
To assay for heparin binding, ϳ10 11 purified genomic particles of virus were loaded onto a 1-ml HiTrap heparin column (GE Healthcare Life Sciences) previously equilibrated with 150 mM NaCl and 50 mM Tris at pH 7.5. The virus was eluted with 0.75-ml volumes of 50 mM Tris buffer containing increasing increments of 50 mM NaCl up to 750 mM, followed by two 1 M washes. To quantify the amount of infectious virus present in each fraction, 75 l of each elution fraction was added to 2.5 ϫ 10 5 293 cells in 12-well format. At 48 hr postinfection, the fraction of green cells was quantified by flow cytometry (EPICS; Beckman Coulter, Fullerton, CA) at the Berkeley Cancer Research Laboratory (University of California, Berkeley, CA).
To compare cell tropism, either wild-type or mutant rAAV-GFP particles were added to 293T, HeLa, CHO K1, CHO pgsA, and CHO pgsD cell lines at a genomic multiplicity of infection (MOI) of 1000. After 48 hr, the fraction of green cells was quantified by flow cytometry (EPICS) at the Berkeley Cancer Research Laboratory. Antibody neutralization assays using human intravenous immunoglobulin (IVIG; Bayer Biological Products, Research Triangle Park, NC) were performed as previously described (Maheshri et al., 2006) .
Animal surgeries and histology
Recombinant AAV vectors were stereotaxically injected into the striatal region of the brain (anteroposterior [AP], ϩ0.2; mediolateral [ML], Ϯ3.5; dorsoventral [DV], -4.5 from skull) of adult female Fischer 344 rats (150 g, 6 weeks old). The animals were deeply anesthetized with a mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg) before injection, and 3 l of high-titer AAV vector (1 ϫ 10 9 vector genomes [VG]/l) was injected with a Hamilton syringe. Animals were transcardially perfused with 4% paraformaldehyde (PFA) in phosphatebuffered saline (PBS), and the brains were excised either 3 days or 3 weeks postinjection, to detect immune responses (n ϭ 2 per condition) or to quantify GFP expression (n ϭ 3 per condition), respectively. The retrieved brains were postfixed by immersion in 4% PFA overnight at 4°C and subsequently stored in 30% sucrose for cryoprotection before sectioning.
Coronal sections (thickness, 40 m) were cut with a freezing, sliding microtome. Primary mouse anti-macrophages/ monocytes (clone ED-1, diluted 1:100; Chemicon International, Temecula, CA) and mouse anti-CD8 ␣ chain (clone OX-8, diluted 1:100; Chemicon International) were used to detect antigens expressed by macrophages and T cells, respectively. In addition, primary mouse anti-neuron-specific nuclear protein (NeuN, diluted 1:200; Chemicon International) and guinea pig anti-glial fibrillary acidic protein (GFAP, diluted 1:1000; Advanced ImmunoChemical, Long Beach, CA) were used to identify cell types (i.e., neurons and glial cells), and GFP expression was amplified with primary rabbit anti-GFP (diluted 1:2000; Invitrogen). Corresponding secondary antibodies (labeled with Alexa Fluor 488, 546, and 633) were used for detection. For nuclear staining, some sections were counterstained with TO-PRO-3 (diluted 1:2000; Invitrogen). The sections containing regions exhibiting GFP expression were collected, and the total volume of GFP expression was quantified by a modified stereology method (Yu and Schaffer, 2006 
RESULTS
Construction of AAV mutants containing His 6 tag
We constructed a library of cap-Cam R insertion mutants, using a MuA transposase and a modified transposon insert containing a chloramphenicol resistance gene (Cam R ). The resulting cap-CAM R library was cloned into the AAV vector pSub2, and the Cam R gene was subsequently replaced with a His 6 -encoding insert to create the final library. Five nucleotides from cap become duplicated at the insertion site during the transposition reaction, and these together with the His 6 sequence yield a 13-amino acid insertion. Restriction digest analysis of individual clones from the library confirmed that the insertions occurred throughout the entire cap gene and that each of these clones contained only one insert (data not shown). The estimated diversity of the library was ϳ5 ϫ 10 4 independent insertions into the 2.6-kb cap PCR product, which thus likely provides full coverage of all possible insertion sites. The library was significantly diluted and used to package replication-competent AAV (rcAAV), as we have previously described for AAV library packaging (Maheshri et al., 2006) .
Although the library likely contains every insertion site, the flanking residues for the His 6 tag, which consist of four alanine residues along with three random amino acids, may decrease infectivity because of the large insertion size or may not be optimal for display of the His 6 tag. Therefore, in parallel, we constructed a series of defined cap-His 6 insertion mutants by spliced overlap extension PCR. These AAV2 insertion sites, previously shown to be permissive to the insertion of peptide sequences, were located in three regions: immediately after amino acid position 584 (Shi et al., 2001) , after amino acid position 587 (Girod et al., 1999) , and after amino acid position 588 (Grifman et al., 2001) (Fig. 1A) . In addition, an AAV8 mu- tant containing the peptide insertion in an analogous loop, after amino acid position 590, was constructed. Each insert contained a His 6 sequence flanked by leucine and glycine on the N-terminal side and serine on the other to aid in efficient peptide display (Fig. 1B) . These mutant cap variants were inserted into a modified AAV helper plasmid, pXX2Not, based on pXX2 (Xiao et al., 1998) .
Analysis of packaging and Ni-NTA-binding ability of AAV clones
To select the cap-His 6 random insertion library for variants capable of binding to Ni-NTA resin, while retaining viral infectivity, the viral library was passed through an Ni-NTA column. The virus present in the elution fractions was then amplified at a low MOI in 293T cells, followed by the addition of adenovirus serotype 5 (Ad5) to induce replication of the infectious AAV variants, which were again applied to the Ni-NTA column. After only two such rounds of selection, sequence analysis of the library indicated that the pool contained one dominant clone with an insertion after amino acid position 454, which bound to the Ni-NTA column at levels greatly exceeding that of wild-type AAV2 (data not shown). The resulting His 6 -cap gene, along with a corresponding His 6 -cap gene in which the His 6 tag was rationally inserted at position 454 with the same leucine, glycine, and serine flanking amino acids used in the other defined insertion clones, were then inserted into pXX2Not. These constructs along with the other rationally designed His 6 clones were then used to package rAAV-GFP.
Initial characterization of both the library-derived His 6 -AAV clone and rationally designed His 6 -AAV variants indicated, surprisingly, that only one (His-587) produced high-titer, infectious virus (Ͼ10 5 IU/ml). Initial, small-scale production on a 10-cm plate yielded ϳ4 ϫ 10 6 IU/ml in clarified cell lysate for this His 6 mutant, compared with ϳ3 ϫ 10 7 IU/ml for wild-type AAV2 capsid. The remaining AAV2 clones, including the variant with the insertion at amino acid 454 identified from the viral library, packaged virus with poor infectivity, that is, with genome:infectious ratios of Ͼ10 5 (data not shown). Optimization of the transposition reaction, which incorporates an additional five amino acids onto each peptide insertion, may require the use of alternative transposases or extensive mutagenesis work to remove the extraneous nucleotides or the addition of several rounds of amplification before selection, despite the fact that the analogous approach worked effectively in the generation of His-tagged vesicular stomatitis virus protein for retroviral and lentiviral purification (Yu and Schaffer, 2006) . It is possible that the need for viral proteins to assemble into a 60-mer capsid, rather than a trimer envelope protein, places additional constraints on the insert location and sequence.
Importantly, the AAV2 variant with a His 6 tag inserted after amino acid 587 (His 6 AAV2), when applied to the Ni-NTA column in clarified cell lysate, bound at levels vastly exceeding that of wild-type AAV2 ( Fig. 2A and B) . Further optimization of incubation times, buffer pH, wash conditions, and elution conditions, using the His 6 AAV2 clone, resulted in a total infectious virus recovery exceeding 90% in a relatively small volume (ϳ1-2 ml). Interestingly, only a moderate 10% of the total DNase-resistant AAV2 viral genomes were recovered from the column, indicating the presence of a large population of noninfectious, DNase-resistant genomes in the crude lysate that were unable to bind to the column. This result is consistent with prior peptide insertions into this region of the AAV2 capsid (Wu et al., 2000; Shi et al., 2001) .
In parallel, the His 6 AAV8 variant, containing an identical peptide insertion after amino acid 590, showed no significant difference in viral production levels. Remarkably, on application of His 6 AAV8 to the Ni-NTA column, more than 90% of both the DNase-resistant viral genomes and infectious virions were recovered from the column ( Fig. 2A and B) , in marked contrast to the His 6 AAV2 results.
We scaled up the purification and generated high-titer rAAV2-GFP by the direct application of clarified crude lysate to a column packed with Ni-NTA resin and elution of the bound virus with high concentrations of imidazole. We also generated high-titer rAAV2-GFP with the wild-type AAV2 capsid by a conventional two-step purification procedure (i.e., centrifugation through an iodixanol gradient followed by flow through a heparin column) (Zolotukhin et al., 1999) . To assess viral purity, SDS-PAGE analysis followed by silver staining was conducted on the IMAC column-purified virus compared with conventional iodixanol and heparin column-purified rAAV2-GFP (Zolotukhin et al., 1999) . The result indicated a negligible difference between the purities of the final viral stocks (Fig. 2C , lane 5 vs. lane 9 in the intentionally overdeveloped silverstained gel), and Western blot analysis confirmed the presence of the His 6 tag within all three viral capsid proteins (Fig. 2D) .
In vitro characterization of His 6 -tagged AAV
Because the His 6 insertion occurs within a region of the AAV2 capsid important for heparan sulfate binding (Kern et al., 2003; Opie et al., 2003) , we further analyzed the properties of His 6 AAV2 in vitro. Both purified His 6 AAV2 and vector packaged in wild-type capsid were loaded onto a heparin column and eluted with a series of increasing salt concentrations, and infectious viral titers within each fraction were determined by flow cytometry. Wild-type AAV2 eluted in a sharp peak from 400 to 500 mM NaCl, consistent with previous reports (Clark et al., 1999; Maheshri et al., 2006) , whereas His 6 AAV2 eluted in a broad range, beginning at 200 mM NaCl and followed by a long tail stretching to 750 mM NaCl, indicating a mixed population of infectious virions with variable heparin affinities (Fig. 3A) .
In addition, several cell lines possessing various levels of heparan sulfate were employed to analyze the cell tropism of the mutant relative to wild-type AAV2 (Fig. 3B) . Infection of 293T and HeLa cell lines showed a modest 2-to 4-fold reduction in the ratio of infectious to genome titers of His 6 AAV2, respectively, compared with wild-type AAV2. However, this difference increased to almost 10-fold on the native CHO K1 cell line and two mutant cell lines, CHO pgsA and pgsD, defective in HSPG biosynthesis (Esko et al., 1985) , indicating that the mutant was more sensitive to lower HSPG levels, likely because of disruption of the heparan sulfate-binding region on the viral capsid. Previous reports from ourselves and others indicated that peptide insertion or a single point mutation within this region conferred moderate resistance to antibody neutralization (Huttner et al., 2003; Maheshri et al., 2006) . Consistent with these findings, the His 6 insertion conferred to the viral vector a ϳ6-fold improvement in gene delivery relative to wildtype AAV2 in the presence of pooled intravenous human immunoglobulin (IVIG) (Fig. 3C) .
In vivo performance of AAV vectors
Vector purification methods should yield viral vectors with high in vivo biological activity, while minimizing any immunogenic response arising from contaminants. IMAC-purified His 6 AAV2 and iodixanol/heparin column-purified AAV2 (1 ϫ 10 9 DNase-resistant particles/l), carrying cDNA encoding GFP driven from a human cytomegalovirus (CMV) promoter, were stereotactically injected into the rat striatum. Two weeks postinjection, robust GFP expression was observed in all animals, and the cellular tropism of His 6 AAV2 remained identical to that of vector packaged with wild-type capsid, with infection primarily of cells staining positive for the neuronal marker NeuN, with minimal apparent infection of cells expressing the astrocytic marker GFAP (Fig. 4A and B) . Interestingly, a small number of neurons exhibited GFP expression adjacent to the needle track only 3 days after injection of both vectors (data not shown). In addition, there was no statistically significant difference in viral infection spread along the anterior-posterior axis or the total volume accessed by viral vector infection between the two viral preparations (Fig. 4C and D) , indicating that the His 6 AAV2 variant is highly efficient in vivo and that its performance is not substantially affected by altered heparin affinity. A potential concern for gene therapy is the development of a host immune response against the injected vi- ral vector (Manno et al., 2006) . Three days postinjection, minimal activation of either CD8-positive T lymphocytes or macrophages was observed with either viral vector ( Fig. 4E and F ). Control injections with PBS exhibited similar low activation levels of macrophages and few CD8-positive T lymphocytes (data not shown).
DISCUSSION
Column chromatography-based viral vector purification offers high vector yields and throughput with low levels of contaminants compared with conventional density gradient purifications. Column platforms based on either affinity-or ionexchange chromatography have successfully permitted rapid, efficient purification of multiple AAV serotypes (Grimm et al., 1998; Clark et al., 1999; Zolotukhin et al., 1999; Auricchio et al., 2001; Walters et al., 2001; Brument et al., 2002; Kaludov et al., 2002) ; however, the variable capsid properties of each serotype force novel affinity systems or purification conditions to be continuously redesigned. Advances in genetic engineering permit the customized design of AAV vectors for improved gene delivery, often based on insertion of exogenous peptide sequences into the viral capsid Maheshri et al., 2006) . However, significant challenges, such as the design of proper flanking sequences or the location of alternate insertion sites, can hinder the use of rational design to identify optimal insertion sites or amino acids critical for the novel vector property. In addition, the local protein environment strongly affects the functional display of a foreign peptide, and a single amino acid change in its sequence may dramatically reduce vector production or infectivity (Wu et al., 2000; Shi et al., 2001) . Joint application of rationally designed AAV capsids and a combinatorial library of capsid variants, created via the random insertion capabilities of transposases, may assist in the rapid design of customized viral gene delivery vectors. Here, we have constructed a large cap-His 6 insertion library likely containing variants with insertions at every internucleotide site of the entire AAV2 cap gene. In parallel, we generated rational AAV cap-His 6 mutants based on locations previously shown to be amenable to foreign peptide insertion (Girod et al., 1999; Grifman et al., 2001; Shi et al., 2001) . Subsequent, iterative rounds of library selection over immobilized metal resin and amplification in 293T cells resulted in the isolation of a dominant, Ni-NTA binding AAV2 mutant. Upon characterization of the viral production ability of both this dominant His 6 AAV mutant and the rational insertions, however, we found that only one mutant, with an insertion after amino acid site 587, was capable of efficiently packaging high-titer rAAV2. In addition, an AAV8 mutant with an insertion in the analogous region of the capsid (after amino acid site 590) was capable of packaging high-titer rAAV, representing to our knowledge the first peptide insertion into the AAV8 capsid. The extension of the (His 6 ) insertion to AAV8 enhances the utility of the approach, as AAV8 has been shown to be highly efficient in delivery to hepatocytes, skeletal and cardiac muscle, and dopaminergic neurons (Conlon et al., 2005; Wang et al., 2005; Klein et al., 2006) . For AAV2, interestingly, the shift of the insertion site by one amino acid from amino acid 587 to amino acid 588, drastically reduced viral infectivity, highlighting the crucial importance of insert location and flanking sequences for optimal function of a peptide insert. Surprisingly, the dominant clone identified from the highthroughput library selection, with the insert located after amino acid 454, bound Ni-NTA resin, but failed to yield infectious virus and was thus not further pursued.
IMAC-PURIFIED ADENO-ASSOCIATED VIRUS
The loop III and loop IV regions within the AAV capsid have been used for peptide insertions with various degrees of success. The loop III region is located at the apex of the 3-fold proximal peaks on the capsid , and deletion of this region has been shown to result in a Ͼ20-fold reduction in viral infectivity (Grifman et al., 2001) . A variety of peptide insertions within this region have been performed with various degrees of success. Insertion of some peptides such as L14 (containing the RGD motif of laminin fragment P1) (Girod et al., 1999) , NGR (Grifman et al., 2001) , and hemagglutinin (HA) (Wu et al., 2000) resulted in infectious virus with a functionally displayed peptide epitope, whereas insertion of other peptides such as luteinizing hormone (LH) (Shi et al., 2001 ) and serpin (Wu et al., 2000) abolished viral infectivity. On the other hand, the other insertion sites studied occur within the wellstudied loop IV (amino acids 583-590) of the AAV capsid. In the case of AAV2, this region is crucial for HSPG binding, and peptide insertions that decrease HSPG binding correlate with at least 100-to 1000-fold decreases in viral infectivity (Girod et al., 1999; Grifman et al., 2001; Shi et al., 2001) , whereas peptide insertions within analogous regions of several alternative AAV serotypes have been well tolerated with no drastic reduction in viral infectivity (Arnold et al., 2006) . These results suggest that although this region (loop IV) provides an optimal location for efficient peptide display within multiple AAV serotypes, peptide insertions into this region have the potential to disrupt structural motifs crucial for the native viral tropism or other biological functions. The results of previous studies, together with the His 6 mutants described above, therefore highlight the need to customize both flanking amino acids and insertion site for each novel peptide, especially for retargeting applications.
Protein engineering techniques in general have the potential to aid in the development of a rapid, robust purification platform for viral vectors. A previous study generated an AAV2 mutant containing a His 6 tag along with a flexible linker at the carboxyl terminus of VP3 through simultaneous transfection of the viral genes for VP1-VP2 and VP3 under the control of the nonnative CMV promoter (Zhang et al., 2002) . Although successful purification of rAAV vectors via Ni-NTA column chromatography was reported, important quantitative parameters such as purity and yield were not included, nor were purified vectors analyzed for efficient in vivo delivery efficiency (Wu et al., 2000) . Thus, a novel insertion site for a His 6 tag in the AAV capsid for the production of high-titer rAAV offers advantages. This study identifies such an insertion site within multiple AAV serotypes and extends the use of high-yield and extremely pure His 6 AAV2, purified via a Ni-NTA column, for gene delivery to the central nervous system with no appreciable host immune response. One study demonstrated that the successful insertion of a biotin acceptor peptide into several locations of multiple AAV serotypes facilitated novel AAV vector purification via a monomeric avidin column (Arnold et al., 2006) . The yields and purity of vectors of several serotypes were promising, although an initial fractionation step via ultracentrifugation in an iodixanol gradient was necessary to remove biotinylated cellular proteins and free biotin. Also, the extremely high affinity between biotin and even monomeric avidin resulted in viral retention on the column (Parrott et al., 2003) , whereas metal-binding tags can offer a moderate-affinity, reversible linkage with immobilized metal columns.
These novel His 6 AAV2 and AAV8 mutants facilitated rapid, robust purification of Ͼ90% recovery of infectious rAAV within clarified crude lysate, which compares well with previous affinity-and ion-exchange chromatography methods. The AAV2 variant capable of producing high-titer virus contained the His 6 tag within a region (amino acids 585-588) that facilitates HSPG binding (Kern et al., 2003; Opie et al., 2003) and therefore may alter the natural tropism of the virus. The heparin column chromatogram indicates that the infectious viral particles contain a range of affinities for heparin, with the majority exhibiting a lower affinity that could allow for improved transport through extracellular matrix regions in tissues that contain high levels of HSPG (Fig. 3A) . Although the reduction in heparin affinity associated with a peptide insertion within this region has been reported (Wu et al., 2000; Shi et al., 2001) , we hypothesize that the presence of a fraction of virus with wild-type or apparently even higher heparin affinity could be due in part to the inherent affinity of His 6 tags for heparin (Lacy and Sanderson, 2002) . However, the broad range of heparin affinities suggests other factors such as salt concentration may alter the pK a of histidine (Lee et al., 2002) and hence alter the degree of protonation within the heparan sulfate-binding region. Furthermore, the observed reduced infectivity on several CHO cell lines (Fig. 3B ) defective in HSPG biosynthesis advances the idea that overall this vector is more sensitive to cell surface levels of HSPG, although this sensitivity did not compromise in vivo delivery. These results agree with our previous study in which an AAV2 mutant with lower affinity for heparin exhibited a similar reduction of infectivity on several CHO cell lines, suggesting that the mutant uses an HSPG-mediated infection pathway (Maheshri et al., 2006) . In addition, whereas the recovery of infectious virions from the column is similar for AAV2 and AAV8, dramatic differences occurred in the fraction of the genome-containing particles present in the flowthrough for these two serotypes. The large fraction of AAV2 genome-containing particles in the flowthrough could represent virions with an altered structural display of the His 6 tag that interferes with HSPG binding and hence viral infectivity, whereas AAV8 does not show a similar trend, suggesting this loop could be relatively less important for facilitating binding to cellular receptors. In addition, the contrasting results for these two AAV serotypes highlight the challenges that may occur when translating a peptide insertion from one AAV serotype to the analogous region in an alternative AAV serotype. Three weeks after purified vector injection into the rat striatum, viral tropism and gene expression were similar for vectors packaged with His 6 AAV2 and wild-type capsid ( Fig. 4A and  B) . Previous studies in the brain showed increased rAAV spread and volume accessed for AAV serotypes that do not bind HSPG (Davidson et al., 2000; Burger et al., 2004) or when low molecular weight heparin was coinfused with AAV2 (Nguyen et al., 2001; Hadaczek et al., 2004) . Interestingly, in this study the reduced affinity of a fraction of His 6 AAV2 for heparin (Fig.  3A) did not translate into enhanced spread within the brain, which contains high amounts of HSPG, potentially because an even moderate affinity for heparan sulfate could be sufficient to hinder free diffusion of the vector. However, our data collectively demonstrate that the gene delivery properties of His 6 AAV2 and wild-type AAV capsid are comparable both in vivo and in vitro.
Robust production methods of highly purified rAAV vectors will enhance the applicability of AAV as a gene delivery vector while minimizing a host immune response. Prior work involving injection of rAAV vectors purified by CsCl, affinity, and ion-exchange methods has shown that AAV itself does not result in significant activation of macrophages, microglia, and CD4-positive or CD8-positive T lymphocytes Sanftner et al., 2004) . Purification of His 6 AAV2 via IMAC resulted in similar basal levels of immune cell activation, further supporting the use of His 6 AAV2 vectors for in vivo gene delivery ( Fig. 4E and F) .
In summary, we report the construction of novel His 6 AAV mutants for two serotypes that can be easily and effectively purified directly from cell lysate, using a single-step IMAC column for safe and efficient in vitro and in vivo gene delivery. His 6 tags may prove useful for other applications, such as the attachment of fluorophore via a Ni-NTA linkage (Kapanidis et al., 2001 ) for viral tracking, or for the localization of viral vectors to cells expressing pseudo-His tag receptors (Grandi et al., 2004) . In addition, the random peptide insertion approach described in this work has significant promise for viral vector engineering, but its application to AAV may require optimization of peptide size and flanking sequences before use. With such adaptations, it may allow for the identification of novel insertion sites within other AAV serotypes. Ultimately, the combination of rational design and large diverse viral libraries will aid in the engineering of viral vectors for improved gene delivery.
